New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Stock Information for Abeona Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Abeona Therapeutics Inc.

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
Artelo Biosciences Announces Proposed Underwritten Public Offering
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.